| Systematic (IUPAC) name | |
|---|---|
| [[(3RS,3'RS)-3,3'-[(2,2-Dimethyltrimethylene)diimino][di-2-butanone]dioximato](3-)-N,N',N'',N''']oxotechnetium (99mTc) | |
| Clinical data | |
| Licence data | US FDA:link |
| Pregnancy cat. | ? |
| Legal status | ℞-only (US) |
| Routes | Intravenous |
| Identifiers | |
| CAS number | 100551-63-1 (exametazime) |
| ATC code | V09AA01 V09HA02 (labelled leucocytes) |
| PubChem | CID 9552069 |
| Chemical data | |
| Formula | C13H25N4O3Tc |
| Mol. mass | 384.3655 g/mol |
| (what is this?) (verify) |
|
Technetium (99mTc) exametazime (trade name Ceretec) is a drug used for the detection of altered regional cerebral perfusion in stroke[1] and other cerebrovascular diseases, and for the labelling of leukocytes to localise intra-abdominal infections[2] and inflammatory bowel disease[3].
The drug consists of two of the three stereoisomers of hexametazime (HMPAO), one of which is shown here, the other being its enantiomer.[4] The third stereoisomer is the meso form. Exametazime acts as a chelating agent for the radioisotope technetium-99m.